Les actionnaires d’Hyloris adoptent toutes les résolutions de l’Assemblée Générale Annuelle
13. Juni 2023 11:59 ET
|
Hyloris Pharmaceuticals SA
56,22% des actions représentées physiquement, virtuellement ou par le biais d’une procurationTous les documents relatifs à l’AG 2023 sont disponibles sur le Site Web Hyloris Information réglementée -...
Hyloris shareholders approve all resolutions at the Annual General Meeting
13. Juni 2023 11:59 ET
|
Hyloris Pharmaceuticals SA
56,22% of shares represented physically, virtually or by proxy voteAll documents related to the 2023 AGM are available on the Hyloris website Regulated Information – Inside Information - Liège,...
Hyloris publie son rapport annuel 2022 et ses objectifs ESG
28. April 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Publication du rapport annuel de l'exercice 2022Objectifs environnementaux, sociaux et de gouvernance, exposés dans le rapport initial sur ESGAssemblée Générale des actionnaires le mardi 13 juin 2023 ...
Hyloris releases Annual Report 2022, including ESG objectives
28. April 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Publication of the annual report for financial year 2022Environmental, Social and Governance objectives disclosed in initial report on ESGAnnual Shareholders Meeting on Tuesday, 13th of June 2023 ...
Hyloris Pharmaceuticals élargit son portefeuille avec un produit candidat pour le traitement de la déficience minérale dans le sang (l’hypophosphatémie)
20. Januar 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
- Hyloris vise à obtenir l’approbation réglementaire en Europe, avec des extensions hors Europe possibles - Environ 5% des patients hospitalisés est diagnostiqué chaque année en hypophosphatémie1,...
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia)
20. Januar 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris targets regulatory approval in Europe, with possible further extensionsAbout 5% of hospitalized patients is diagnosed with hypophosphatemia, with part of them needing direct treatment during...
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
05. März 2021 01:00 ET
|
Hyloris Pharmaceuticals
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets Footprint across Europe now extended to a total of 20 EU member states ...
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer
01. Oktober 2020 07:00 ET
|
Hyloris Pharmaceuticals
Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer Liège, Belgium – 1 October 2020: Hyloris Pharmaceuticals SA, an innovative specialty pharmaceutical company focused on adding value to...
Hyloris announces approval of Maxigesic® IV in eight European countries
07. September 2020 04:37 ET
|
Hyloris Pharmaceuticals
Hyloris announces approval of Maxigesic® IV in eight European countries Commercialization of Hyloris’ second marketed product to start in early 2021 Liège, Belgium – 7 September 2020 – Hyloris...
Publication of transparency notifications
06. Juli 2020 12:30 ET
|
Hyloris Pharmaceuticals
PRESS RELEASE Publication of transparency notifications Liège (Belgium), 6 July 2020, 18h30 (CEST) – regulated information – In accordance with article 14 of the Act of 2 May...